The closed and automated DynaCellect instrument enables accurate cell isolation, cell activation, cell depletion and Dynabeads magnetic beads removal.
It seeks to enable cell therapy developers to smoothly transition from clinical development to commercial manufacturing by offering a scalable, flexible and end-to-end closed system.
The system will help developers ensure that the right cells are isolated, thus reducing shortcomings in manufacturing.
Both DynaCellect and Dynabeads will allow manufacturers to increase the pace of protocol design and commercial production and will also offer multiple and effective therapy options for patients.
Thermo Fisher Scientific cell culture and cell therapy vice-president and general manager Tiffani Manolis said: “The future of cell therapy is bright, and our team is focused on innovations that expedite breakthroughs and, ultimately, help patients.
“DynaCellect helps minimise the potential for errors while accelerating the manufacturing process.
“This allows our customers to commercialise therapies faster and potentially save more lives. It is a perfect example of how our innovations deliver on our commitment to helping our customers make the world healthier.”
The modular feature of the new system enables it to be used either as a standalone device or integrated with the Gibco CTS ROTEA Counterflow Centrifugation System and the Gibco CTS XENON Electroporation System.
Additionally, DynaCellect provides process scalability for autologous and allogeneic workflows.
In March, Thermo Fisher Scientific introduced the Ion Torrent Genexus Dx Integrated Sequencer platform for use in clinical laboratories.